XGEVA is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Amgen Inc. The primary component is Denosumab.
Product ID | 55513-730_201abd85-c4ed-424f-8e79-ca1c34368d06 |
NDC | 55513-730 |
Product Type | Human Prescription Drug |
Proprietary Name | XGEVA |
Generic Name | Denosumab |
Dosage Form | Injection |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2010-11-18 |
Marketing Category | BLA / BLA |
Application Number | BLA125320 |
Labeler Name | Amgen Inc |
Substance Name | DENOSUMAB |
Active Ingredient Strength | 120 mg/1.7mL |
Pharm Classes | RANK Ligand Inhibitor [EPC],RANK Ligand Blocking Activity [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2010-11-18 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA125320 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-11-18 |
Ingredient | Strength |
---|---|
DENOSUMAB | 120 mg/1.7mL |
SPL SET ID: | 628f0998-1206-4001-aeee-18133aa9f3bf |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
55513-730 | XGEVA | denosumab |
55513-710 | Prolia | denosumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
XGEVA 78944422 3921172 Live/Registered |
Amgen Inc. 2006-08-03 |